MOR106 is the first publicly disclosed human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is also the first antibody from MorphoSys’s Ylanthia platform to enter clinical development. In preclinical models, IL-17C has been shown to play an important role in inflammatory skin disorders. We are developing MOR106 in collaboration with our partner, Galapagos. MOR106 is currently in clinical development for the treatment of atopic dermatitis, a debilitating chronic inflammatory skin disease. A randomized placebo-controlled phase 1 study, testing MOR106 in healthy volunteers and in patients suffering from atopic dermatitis, was successfully completed. A subsequent phase 2 study stared in the quater of 2018.